{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:55:39Z","timestamp":1790776539768,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014421","name":"EA Pharma Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"Astrazeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda Pharmac"},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10388-020-00792-z","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T11:24:52Z","timestamp":1604316292000},"page":"398-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The early therapeutic response at 2\u00a0weeks is a crucial predictor of proton pump inhibitor-refractory gastroesophageal reflux disease"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8742-5284","authenticated-orcid":false,"given":"Maiko","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Arihiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Joh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Isshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hokari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Oshio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Haruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"792_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrgastro.2016.50","volume":"13","author":"S Emidio","year":"2016","unstructured":"Emidio S, Daphne A, Ans P, et al. Management of refractory typical GERD symptoms. Nat Rev Gastroentelogy & Hepatology. 2016;13:281\u201394.","journal-title":"Nat Rev Gastroentelogy & Hepatology"},{"key":"792_CR2","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","volume":"51","author":"K Iwakiri","year":"2016","unstructured":"Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751\u201367.","journal-title":"J Gastroenterol"},{"key":"792_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1471-230X-11-52","volume":"11","author":"RC Heading","year":"2011","unstructured":"Heading RC, M\u00f6nnikes H, Tholen A, et al. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol. 2011;11:52.","journal-title":"BMC Gastroenterol"},{"key":"792_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gutjnl-2011-300798","volume":"61","author":"F Zerbib","year":"2012","unstructured":"Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut. 2012;61:501\u20136.","journal-title":"Gut"},{"key":"792_CR5","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.3748\/wjg.v19.i20.3124","volume":"19","author":"XP Niu","year":"2013","unstructured":"Niu XP, Yu BP, Wang YD, et al. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease. World J Gastroenterol. 2013;19:3124\u20139.","journal-title":"World J Gastroenterol"},{"key":"792_CR6","first-page":"1563","volume":"11","author":"Y Hoshihara","year":"1996","unstructured":"Hoshihara Y. GERD-gastroesophageal reflux disease endoscopic diagnosis and classification. Rinshou Shoukakinaika. 1996;11:1563\u20138.","journal-title":"Rinshou Shoukakinaika"},{"issue":"95\u20139","key":"792_CR7","first-page":"18","volume":"41","author":"M Hongo","year":"2006","unstructured":"Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol. 2006;41(95\u20139):18.","journal-title":"J Gastroenterol"},{"key":"792_CR8","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.3748\/wjg.v23.i28.5216","volume":"23","author":"K Nakada","year":"2017","unstructured":"Nakada K, Matsuhashi N, Iwakiri K, et al. Development and validation of a simple and multifaceted instrument, GERD-TEST, for the clinical evaluation of gastroesophageal reflux and dyspeptic symptoms. World J Gastroenterol. 2017;23:5216\u201328.","journal-title":"World J Gastroenterol"},{"key":"792_CR9","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates Publishers; 1988.","edition":"2"},{"key":"792_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5056\/jnm.2014.20.1.6","volume":"20","author":"C Maradey-Romero","year":"2014","unstructured":"Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014;20:6\u201316.","journal-title":"J Neurogastroenterol Motil"},{"key":"792_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s005350050292","volume":"34","author":"T Soga","year":"1999","unstructured":"Soga T, Matsuura M, Kodama Y, et al. Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis? J Gastroenterol. 1999;34:435\u201340.","journal-title":"J Gastroenterol"},{"key":"792_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/1756283X17705329","volume":"10","author":"K Iwakiri","year":"2017","unstructured":"Iwakiri K, Sakurai Y, Shiino M, et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Ther Adv Gastroenterol. 2017;10:439\u201351.","journal-title":"Ther Adv Gastroenterol"},{"key":"792_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-2036.2007.03350.x","volume":"26","author":"H Miwa","year":"2007","unstructured":"Miwa H, Sasaki M, Furuta T, et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007;26:69\u201377.","journal-title":"Aliment Pharmacol Ther"},{"key":"792_CR14","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","volume":"112","author":"N Chiba","year":"1997","unstructured":"Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798\u2013810.","journal-title":"Gastroenterology"},{"key":"792_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s00535-006-1804-3","volume":"41","author":"Y Kinoshita","year":"2006","unstructured":"Kinoshita Y, Kobayashi T, Kato M, et al. The pharmacodynamics effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. J Gastroenterol. 2006;41:554\u201361.","journal-title":"J Gastroenterol"},{"key":"792_CR16","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jgh.14664","volume":"34","author":"H Miyazaki","year":"2019","unstructured":"Miyazaki H, Igarashi A, Takeuchi T, et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. J Gastroenterol Hepatol. 2019;34:1316\u201328.","journal-title":"J Gastroenterol Hepatol"},{"key":"792_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00535-011-0488-5","volume":"47","author":"K Tominaga","year":"2012","unstructured":"Tominaga K, Iwakiri R, Fujimoto K, et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol. 2012;47:284\u201392.","journal-title":"J Gastroenterol"},{"key":"792_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00535-015-1073-0","volume":"50","author":"N Matsuhashi","year":"2015","unstructured":"Matsuhashi N, Kudo M, Yoshida N, et al. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study. J Gastroenterol. 2015;50:1173\u201383.","journal-title":"J Gastroenterol"},{"key":"792_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2036.2006.02983.x","volume":"24","author":"NJ Talley","year":"2006","unstructured":"Talley NJ, Armstrong D, Junghard O, et al. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2006;24:371\u20136.","journal-title":"Aliment Pharmacol Ther"},{"key":"792_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1046\/j.1365-2036.2003.01651.x","volume":"18","author":"E Bolling-Sternevald","year":"2003","unstructured":"Bolling-Sternevald E, Lauritsen K, Talley NJ, et al. Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther. 2003;18:117\u201324.","journal-title":"Aliment Pharmacol Ther"},{"key":"792_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.dld.2005.04.026","volume":"37","author":"F Pace","year":"2005","unstructured":"Pace F, Annese V, Prada A, et al. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease: a randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis. 2005;37:741\u201350.","journal-title":"Dig Liver Dis"},{"key":"792_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1080\/00365520600615781","volume":"41","author":"P Bytzer","year":"2006","unstructured":"Bytzer P, Morocutti A, Kennerly P, et al. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand J Gastroenterol. 2006;41:1132\u201340.","journal-title":"Scand J Gastroenterol"},{"key":"792_CR23","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/j.1365-2036.2009.03948.x","volume":"29","author":"A Eggleston","year":"2009","unstructured":"Eggleston A, Katelaris PH, Nandurkar S, et al. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care\u2013prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol Ther. 2009;29:967\u201378.","journal-title":"Aliment Pharmacol Ther"},{"key":"792_CR24","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3748\/wjg.15.990","volume":"15","author":"R-N Zheng","year":"2009","unstructured":"Zheng R-N. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol. 2009;15:990\u20135.","journal-title":"World J Gastroenterol"}],"updated-by":[{"DOI":"10.1007\/s10388-021-00837-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000}}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-020-00792-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-020-00792-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-020-00792-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T05:15:01Z","timestamp":1697001301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-020-00792-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["792"],"URL":"https:\/\/doi.org\/10.1007\/s10388-020-00792-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10388-021-00837-x","asserted-by":"object"}]},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10388-021-00837-x","URL":"https:\/\/doi.org\/10.1007\/s10388-021-00837-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (sixth revision, 2008), after approval by the ethics committee of each institution or the central ethics committee of Nishi Clinic, Osaka, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}},{"value":"Dr. Nobuyuki Matsuhashi received a research grant from Astrazeneca, Takeda Pharm., Eizai. Dr. Katsuhiko Iwakiri received Lecture fees from Takeda Pharmaceutical Co., Ltd., Otsuaka Pharmaceutical Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED, and EA Pharma Co., LTD. Dr. Maiko Ogawa, Dr. Seiji Arihiro, Dr. Takashi Joh, Dr. Kazuhide Higuchi, Dr. Takeshi Kamiya, Dr. Noriaki Manabe, Dr. Kimio Isshi, Dr. Tatsuya Nakada, Dr. Atsushi Hokari, Dr. Masayuki Saruta, Dr. Atsushi Oshio, Dr. Ken Haruma and Dr. Koji Nakada declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all enrolled patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}